Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Warner Music Group Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while Warner Music Group Corp trades at $29.28 (market cap $15.12B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.6× Warner Music Group Corp's market cap, and Warner Music Group Corp pays a 2.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WMG | |
|---|---|---|
Market Cap | $39.89B | $15.12B |
Sector | Health | Media |
52-Week High | $491.22 | $34.72 |
52-Week Low | $278.09 | $23.65 |
Enterprise Value | $38.15B | $19.32B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Warner Music Group (WMG) trades at $28.99, down 0.51% on the day, with a bullish technical signal driven by moving averages but mixed oscillators. The company reported revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. Recent acquisitions like Sureel AI highlight strategic moves in AI-driven music attribution. Analyst consensus is strongly bullish with a $40.40 price target, implying significant upside from current levels.
WMG presents a compelling growth story with solid revenue expansion and strategic AI investments, but faces risks from margin compression and competitive pressures. The stock's high P/E of 34.51 suggests premium valuation, yet strong analyst buy ratings and institutional interest support further upside potential if execution on catalog monetization and streaming growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
